YELENA VERENCHUK: Open Payments
NPI 1770247413 · RICHMOND, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,920 in 80 payments from 11 companies in 2025. Trend: 2023 $933 · 2024 $698 · 2025 $1,920
Food & beverage: $1,920
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $418 |
| Vanda Pharmaceuticals Inc. | 18 | $408 |
| E.R. Squibb & Sons, L.L.C. | 7 | $230 |
| ABBVIE INC. | 20 | $207 |
| Alkermes, Inc. | 8 | $183 |
| Teva Pharmaceuticals USA, Inc. | 3 | $170 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Janssen Pharmaceuticals, Inc | 3 | $78 |
| Biogen, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
Products named: REXULTI, FANAPT, COBENFY, VRAYLAR, HETLIOZ, UZEDY, LYBALVI, Auvelity.
Industry payments across KY — which companies pay providers there.
